Cardiotoxicity of Anti-Cancer Radiation Therapy: a Focus on Heart Failure

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Current Heart Failure Reports

• Publication date

  2023-01-24

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1007/s11897-023-00587-0PMID 36692820
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

  2022cited by this paper
• Cancer statistics, 2022

  2022cited by this paper
• Lack of Cardiotoxicity Endpoints in Prospective Trials Involving Chest Radiation Therapy: A Review of Registered, Latter-Phase Studies

  2022cited by this paper
• Adropin Improves Radiation-Induced Myocardial Injury via VEGFR2/PI3K/Akt Pathway

  2022cited by this paper
• Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

  2022cited by this paper
• Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysis.

  2022cited by this paper
• Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study

  2022cited by this paper
• The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer

  2022cited by this paper
• Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

  2021cited by this paper
• Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

  2021cited by this paper
• Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial

  2021cited by this paper
• A Multi-institutional Analysis of Radiation Dosimetric Predictors of Toxicity Following Trimodality Therapy for Esophageal Cancer.

  2021cited by this paper
• Cardiovascular Event Reporting in Modern Cancer Radiation Therapy Trials

  2021cited by this paper
• Cardiovascular Burden and Adverse Events in Patients With Esophageal Cancer Treated With Chemoradiation for Curative Intent

  2021cited by this paper
• Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography–Directed Therapy for Early-Stage Hodgkin Lymphoma

  2021cited by this paper
• Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis

  2021cited by this paper
• Subclinical left ventricle impairment following breast cancer radiotherapy: Is there an association between segmental doses and segmental strain dysfunction?

  2021cited by this paper
• Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction

  2021cited by this paper
• Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC)

  2020cited by this paper
• Focused echocardiography in cardio‐oncology

  2020cited by this paper
• Immune Checkpoint Inhibitors-Related Cardiotoxicity.

  2020cited by this paper
• Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer.

  2020cited by this paper
• Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617

  2020cited by this paper
• A guide to cancer immunotherapy: from T cell basic science to clinical practice

  2020cited by this paper
• Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients?

  2020cited by this paper
• Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer.

  2020cited by this paper
• Cardiac MRI utilizing late gadolinium enhancement (LGE) and T1 mapping in the detection of radiation induced heart disease

  2020cited by this paper
• Transcatheter Treatment of Residual Significant Mitral Regurgitation Following TAVR: A Multicenter Registry.

  2020cited by this paper
• Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications

  2019cited by this paper
• Cardiac Toxicity in Operable Esophageal Cancer Patients Treated With or Without Chemoradiation

  2019cited by this paper
• A population-based study of cardiovascular disease mortality risk in US cancer patients.

  2019cited by this paper
• Outcomes of Patients With Severe Symptomatic Aortic Valve Stenosis After Chest Radiation: Transcatheter Versus Surgical Aortic Valve Replacement

  2019cited by this paper
• New therapeutic insights into radiation-induced myocardial fibrosis

  2019cited by this paper
• Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.

  2019cited by this paper
• Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer.

  2019cited by this paper
• Prognostic and Added Value of Echocardiographic Strain for Prediction of Adverse Outcomes in Patients with Locally Advanced Non-Small Cell Lung Cancer after Radiotherapy.

  2019cited by this paper
• Novel Radiotherapy Techniques for Breast Cancer.

  2018cited by this paper
• First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer

  2018cited by this paper
• Cardiac radiation dose distribution, cardiac events and mortality in early-stage lung cancer treated with stereotactic body radiation therapy (SBRT).

  2018cited by this paper
• Dosimetric Predictors of Symptomatic Cardiac Events After Conventional‐Dose Chemoradiation Therapy for Inoperable NSCLC

  2018cited by this paper
• Immune checkpoint inhibitors and cardiovascular toxicity.

  2018cited by this paper
• Activity and outcomes of a cardio‐oncology service in the United Kingdom—a five‐year experience

  2018cited by this paper
• Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.

  2017cited by this paper
• Anthracycline Chemotherapy and Cardiotoxicity

  2017cited by this paper
• Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline Summary.

  2017cited by this paper
• Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.

  2017cited by this paper
• Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.

  2017cited by this paper
• Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma

  2017cited by this paper
• Constrictive pericarditis: diagnosis, management and clinical outcomes

  2017cited by this paper
• A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients.

  2017cited by this paper
• Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer

  2017cited by this paper
• Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.

  2017cited by this paper
• Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early‐stage Non–Small‐cell Lung Cancer

  2017cited by this paper
• Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.

  2017cited by this paper
• Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer

  2017cited by this paper
• Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer

  2017cited by this paper
• Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

  2016cited by this paper
• Contemporary Breast Radiotherapy and Cardiac Toxicity.

  2016cited by this paper
• Effect of Breast Irradiation on Cardiac Disease in Women Enrolled in BCIRG-001 at 10-Year Follow-Up.

  2016cited by this paper
• Impaired Right Ventricular Function in Long-Term Lymphoma Survivors.

  2016cited by this paper
• Heart Transplantation Outcomes in Radiation-Induced Restrictive Cardiomyopathy.

  2016cited by this paper
• Assessment of Valvular Disorders in Survivors of Hodgkin's Lymphoma Treated by Mediastinal Radiotherapy ± Chemotherapy.

  2016cited by this paper
• Deep inspiration breath-hold technique in left-sided breast cancer radiation therapy: Evaluating cardiac contact distance as a predictor of cardiac exposure for patient selection.

  2015cited by this paper
• Radiation-Induced Heart Disease: Pathologic Abnormalities and Putative Mechanisms

  2015cited by this paper
• The Role of Radiotherapy in Hodgkin's Lymphoma: What Has Been Achieved during the Last 50 Years?

  2015cited by this paper
• Long-term outcomes of pericardiectomy for constrictive pericarditis

  2015cited by this paper
• Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.

  2015cited by this paper
• Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

  2015cited by this paper
• Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials.

  2015cited by this paper
• Incidental dose to coronary arteries is higher in prone than in supine whole breast irradiation

  2014cited by this paper
• Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors

  2014cited by this paper
• Epigenetics in radiation-induced fibrosis

  2014cited by this paper
• Cardiac transplantation for radiation-induced cardiomyopathy: the Mayo Clinic experience.

  2014cited by this paper
• Dosimetric Evaluation of Critical Organs at Risk in Mastectomized Left-Sided Breast Cancer Radiotherapy Using Breath-Hold Technique

  2013cited by this paper
• A comparative dosimetric study for treating left-sided breast cancer for small breast size using five different radiotherapy techniques: conventional tangential field, filed-in-filed, Tangential-IMRT, Multi-beam IMRT and VMAT

  2013cited by this paper
• Risk of ischemic heart disease in women after radiotherapy for breast cancer.

  2013cited by this paper
• Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinoma.

  2013cited by this paper
• State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review.

  2013cited by this paper
• Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.

  2013cited by this paper
• Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.

  2013cited by this paper
• Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer.

  2012cited by this paper
• Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.

  2012cited by this paper
• Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.

  2012cited by this paper
• Prospective assessment of optimal individual position (prone versus supine) for breast radiotherapy: volumetric and dosimetric correlations in 100 patients.

  2012cited by this paper
• Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma.

  2012cited by this paper
• Radiation during deep inspiration allows loco-regional treatment of left breast and axillary-, supraclavicular- and internal mammary lymph nodes without compromising target coverage or dose restrictions to organs at risk

  2012cited by this paper
• Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.

  2012cited by this paper
• Preoperative chemoradiotherapy for esophageal or junctional cancer.

  2012cited by this paper
• Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin's disease.

  2011cited by this paper
• Acute radiation effects on cardiac function detected by strain rate imaging in breast cancer patients.

  2011cited by this paper
• Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy.

  2011cited by this paper
• Pathogenetic mechanisms in radiation fibrosis.

  2010cited by this paper
• Stereotactic body radiation therapy for inoperable early stage lung cancer.

  2010cited by this paper
• Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?

  2010cited by this paper
• Cardiovascular toxicity caused by cancer treatment: strategies for early detection.

  2009cited by this paper
• Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies

  2006cited by this paper
• Asymptomatic cardiac disease following mediastinal irradiation.

  2003cited by this paper
• Coronary artery bypass grafting in patients with previous mediastinal radiation therapy.

  1999cited by this paper
• Patterns of presentation of Hodgkin disease

  1993cited by this paper
• Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis

  1993cited by this paper

• Cardiotoxicity of Chemoradiotherapy in Patients With Esophageal Cancer: A Systematic Review

  2026cites this paper
• Robustness of heart dose against cardiac cycle in breast cancer radiotherapy with deep inspiration breath-hold

  2026influential citation
• [18F]-FLT-PET to evaluate how the sequencing of chemotherapies impacts the efficacy of combination treatment in mouse models of triple-negative breast cancer

  2025cites this paper
• Linggui Zhugan decoction ameliorating mitochondrial damage of doxorubicin-induced cardiotoxicity by modulating the AMPK-FOXO3a pathway targeting BTG2.

  2025cites this paper
• Cardiovascular Disease Meets Cancer: Exploring the Epidemiology in China and Homotherapy Targeting Intersectional Mechanisms

  2025cites this paper
• Impact of deep inspiration breath-hold (DIBH) on dose distribution and radiobiological effects in left-sided breast irradiation: A comparative study of IMRT and VMAT techniques under DIBH and free breathing conditions

  2025cites this paper
• Building Bridges in Cardio-Oncology: The Role of Clinics in Multidisciplinary Care and Patient Outcomes

  2025cites this paper
• Asymptomatic Lung Adenocarcinoma With Cardiac Metastasis at Initial Diagnosis: A Case Report

  2025cites this paper
• Use of Polygenic Risk Score for Prediction of Heart Failure in Cancer Survivors

  2024cites this paper
• Cardio-Oncology and Heart Failure: A Scientific Statement from the Heart Failure Society of America.

  2024cites this paper
• Curcumin Nanoparticles-related Non-invasive Tumor Therapy, and Cardiotoxicity Relieve

  2024cites this paper
• Development and first implementation of a novel multi‐modality cardiac motion and dosimetry phantom for radiotherapy applications

  2024cites this paper
• Cardiac PET Imaging of ATP Binding Cassette (ABC) Transporters: Opportunities and Challenges

  2023cites this paper